Mirati to Rival Amgen in Solid Tumors

Breaking Biotech
|

Automatic TRANSCRIPT

So to start I wanNA talk about exact sciences ticker symbol e x a s, and they are now trading at around twelve billion dollar market cap, and what they announced is liquid biopsy testing data in six different cancer types showing a sensitivity of eighty six percent and a specificity of ninety five percent, and they did kind of a grab bag of cancer types. We have lung ovarian, liver pancreatic, and Alpha Jill. And so I did video on exact sciences quite a while ago I thought their evaluation was a little bit toppy back then and was waiting for dipped to buy, and that's what I did during the Cova crisis I took a small position and then I sold just recently at around ninety four and I think is trading just over one hundred dollars right now but this. Is Nice to see them kind of moving into new areas because I think one of the things that they're struggling with is leaning on their old testing kit the colours guard while all these other companies are trying to get into things like liquid biopsy, which it's going to be a real game changer in the space. Once these treatments get validated and approved by the FDA. Now. They're not alone doing this exact sciences is kind of just finally getting into this because other big players like alumina through grail they just acquired this private company called grail officially officially. We've garden health personalisation of been floating around and invitations. Well, who just acquired archer DSL there's a lot of companies in the space, but exact scientists has shown some pretty good success in their previous testing kits. So it just makes sense them to jump into this new area and be a good competitor. So I think right now probably a little bit toppy with the price around one hundred but I'm pretty pleased with the small profit. I made given the number shares that I have. So that's exact sciences. Want to move now into regeneration ticker symbol. And they're trading at a sixty billion dollar market CAP. I did a video on them also a few months ago, looking at kind of their staples in terms of the different products that they offer and I concluded that they were relatively over-valued back. Then I think now also a little bit overvalued, but it does depend on how well their product. So and the kind of revenue they can bring in obviously but the news that we heard is that they released data on their antibody cocktail for covid nineteen. and. What we saw is that it reduced viral loads and symptoms versus placebo in non. Patients who are infected with SARS co to and what they shared our results from initial cohort of two hundred and seventy five patients, and they also have nine hundred or more patients enrolled. So this is kind of a preliminary analysis that they're showing US and they've called it a phase one, two, three trials. So they're doing the PK the safety along with the efficacy and other sorts of secondary outcomes all at once and when I look through their stuff, they started off by kind of categorizing patients based. On Sarah Negative or zero positive and I, think it's important that they do this because we're looking at a treatment for covid nineteen and if people are already sero-positive in their bodies, already mounted an antibody response in order to bring down viral loads. So what regeneration is trying to pose here is that the negative patients which means they have not mount that antibody response have significantly higher viral load and they make a better target for most treatments probably also their antibody cocktail that they're gonNA share data with. So. Then the data that they show here shows a range of efficacy based off of viral load. So we have tended the power of four copies, parallel all the way to tend to the seven copies personnel. So quite a big range in viral load here and I just blew this up on the screen. What we're seeing is that at the higher viral load, the treatment and there two different doses here in the green and the red line, we see that much more dramatic decrease in the amount of viral load in. These patients and it does kind of make sense because if your body's already mounted an antibody response, the window of efficacy is just going to be a bit smaller than if it's before the at which your body's manning response. So I think for these patients, it's definitely positive data. They also looked at other other metrics as well and I'm not going to get into everything but they did look at a day to alleviation of symptoms and they looked at the overall population of patients. It's the difference of nine with Placebo. To between six and eight, depending on the dose that they gave the antibody cocktail with the negative group alone, the placebo was thirteen days and then the low and high dose was six and eight respectively. So obviously a big difference when it comes to whether or not the patient is zero negative or positive. So that's probably going to inform the FDA when it comes to approving the drug or giving some kind of guidance on which patients should take the drug and who are likely to see more positive outcomes from that. So overall. I think it's good. It gets a step ahead of the Gilead data where I don't think we've even seen a placebo group yet. So it's nice to see regenerate actually do this placebo controlled trial. We can see whether or not there is efficacy and I, look forward to seeing the rest of the data I'm not if this merits taking a position regenerate here given that they're such a large company already and they have so many different assets that are I would say more likely to contribute to their bottom line. This doesn't entice me to take a position, but it's nice to see that we're getting all these therapies are starting to see vaccine data, and this just makes me feel better in general that we're going to move towards being able to treat this disease and hopefully get out from under this and then Kinda recover with the economy. With that, let's talk about the main story for today, and that is morality Therapeutics Ticker Symbol M rt ex, and they're trading at a price of one sixty, two point zero five per share giving them a market cap of seven point two, billion dollars. Their Q. Two, twenty, twenty, net loss was eighty, three, million dollars, and this represents an eighty percent increase year over year there their q two net current cash is six, hundred million dollars giving them a runway of about until twenty twenty two I would say but let's also be careful that if they see positive data. This year or next year is a good chance that they're going to raise again. And what Morad is trying to do is develop targeted cancer treatments and they're specifically looking at solid tumors and even more specific than that are K. Rasa inhibitors, and so they have to compounds Marta six, eight, four, nine, and x, one, three, three. They're also looking at checkpoint inhibitor resistance with their compound sicher Vance it, and I'll talk about that in a bit later. To start though we gotta talk about chaos and the reason why this is so important is that chaos mutations are present in a large population of cancer patients. The first thing it's important to note is that chaos is pretty ubiquitous. It's a critical part of the map kinase signaling pathway, and this is very important in basically every single cell. This pathways involved in Cell Proliferation Cell Survival had differentiation here. There's a whole bunch of other stuff and it makes a little bit confusing because it is involved in. So many different pathways that if you were just to inhibit this molecule non specifically, you're likely to see significant side effects with patients. It's for this reason that it's important that we can come up with a targeted therapy that will only target cells that have a mutation in chaos rather than the healthy normal. KS. To talk a little bit more about its function, it works as a GT as and what this means is that it takes a molecule GDP converts it to GDP using that phosphate group to continue the signaling pathway. The next step is Raff or something like that mutations in. A company twenty, one point, six percent of all human cancers, and then I have here that chaos the predominant or exclusive Rask's mutated in three of the top four neoplasms that account for cancer deaths in the US lung colon and pancreatic. Cancer.

Coming up next